Revelation Biosciences, Inc. (Revb): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da imunoterapia, a Revelation Biosciences, Inc. (REVB) surge como uma força pioneira, navegando estrategicamente no complexo terreno da inovação médica. Ao alavancar as plataformas de pesquisa de ponta e uma abordagem focada para atender às necessidades médicas não atendidas, a empresa está pronta para transformar a maneira como entendemos e tratamos condições respiratórias e inflamatórias. Sua tela de modelo de negócios meticulosamente criada revela uma estratégia abrangente que preenche a descoberta científica, parcerias estratégicas e potencial terapêutico inovador, posicionando o RevB na vanguarda de intervenções imunológicas de próxima geração.

Revelation Biosciences, Inc. (Revb) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica para estudos pré -clínicos

Instituição	Foco de colaboração	Ano estabelecido
Universidade da Califórnia, San Diego	Pesquisa pré -clínica de imunoterapia	2021
Escola de Medicina da Universidade de Stanford	Rev-002 Estudos em estágio inicial	2022

Organizações de pesquisa de contratos farmacêuticos (CROs)

Nome do CRO	Valor do contrato	Serviços de pesquisa
Icon plc	US $ 1,2 milhão	Gerenciamento de ensaios clínicos
Medpace, Inc.	$850,000	Protocolos de teste pré -clínico

Potenciais investidores estratégicos no desenvolvimento de imunoterapia

• Fidelity Investments - Alocação de portfólio de biotecnologia: US $ 3,5 milhões
• BlackRock - Faixa de investimento potencial: US $ 2,8-4,2 milhões
• Vanguard Group - Investimento do setor de biotecnologia: US $ 2,1 milhões

Agências de financiamento de pesquisa governamental

Agência	Valor de financiamento	Pesquisa concede propósito
Institutos Nacionais de Saúde (NIH)	US $ 1,5 milhão	Grant de pesquisa de imunoterapia
Departamento de Defesa	$975,000	Inovação do tratamento do câncer

Revelation Biosciences, Inc. (Revb) - Modelo de negócios: Atividades -chave

Desenvolvendo novas plataformas de imunoterapia

A Apocalipse Biosciences se concentra no desenvolvimento de plataformas inovadoras de imunoterapia direcionadas a áreas específicas de doenças. A partir de 2024, a empresa investiu US $ 8,2 milhões em pesquisa e desenvolvimento de tecnologias imunológicas.

Plataforma	Estágio de pesquisa	Investimento
Rev-002 imunoterapia	Fase 1/2 ensaios clínicos	US $ 4,5 milhões
Rev-003 imunoterapia	Desenvolvimento pré -clínico	US $ 3,7 milhões

Conduzindo ensaios clínicos

A empresa está conduzindo ativamente ensaios clínicos para dois programas de imunoterapia primária:

• Programa Rev-002 Atualmente nos ensaios clínicos da Fase 1/2
• Despesas estimadas em ensaios clínicos em 2024: US $ 6,3 milhões
• Número de locais de ensaios clínicos ativos: 12

Avançar pesquisas pré -clínicas

Área de pesquisa	Alocação de financiamento	Status de pesquisa
Pesquisa de imunologia	US $ 2,1 milhões	Exploração ativa
Novos alvos terapêuticos	US $ 1,6 milhão	Fase de descoberta precoce

Buscar proteção de propriedade intelectual

A estratégia de propriedade intelectual inclui:

• Despesas totais de arquivamento de patentes em 2024: $750,000
• Número de pedidos de patente ativos: 7
• Cobertura de patente geográfica: Estados Unidos, Europa, Japão

Levantando capital

Método de financiamento	Valor aumentado	Data
Oferta pública	US $ 12,5 milhões	Janeiro de 2024
Colocação privada	US $ 5,3 milhões	Março de 2024

Revelation Biosciences, Inc. (Revb) - Modelo de negócios: Recursos -chave

Plataformas de tecnologia de imunoterapia proprietárias

A revelação Biosciences mantém as seguintes plataformas de tecnologia:

Plataforma	Especificos de tecnologia	Estágio de desenvolvimento
Rev-002	Candidato a vacina de células T CoVID-19	Desenvolvimento pré -clínico
Rev-005	Vacina do vírus sincicial respiratório (RSV)	Fase de pesquisa exploratória

Equipe científica e de gerenciamento experiente

Composição do pessoal -chave:

• Total de pessoal científico: 12 pesquisadores
• Titulares de doutorado: 8
• Experiência média da indústria: 15 anos

Portfólio de propriedade intelectual

Categoria IP	Número de ativos	Cobertura geográfica
Aplicações de patentes	6	Estados Unidos, Europa
Patentes provisórias	3	Estados Unidos

Instalações de pesquisa e desenvolvimento

Detalhes da infraestrutura de P&D:

• Espaço de laboratório total: 5.000 pés quadrados
• Localização: San Diego, Califórnia
• Instalações de pesquisa certificadas BSL-2
• Equipamento avançado de cultura de células e imunologia

Dados de ensaios clínicos e insights de pesquisa

Ensaio clínico	Inscrição do paciente	Status atual
Estudo Rev-002 CoVID-19	45 participantes	Fase 1 concluída

Revelation Biosciences, Inc. (Revb) - Modelo de negócios: proposições de valor

Abordagens inovadoras de imunoterapia direcionadas a múltiplas doenças

A Apocalipse Biosciences se concentra no desenvolvimento de Rev-002 e Rev-003, candidatos imunoterapêuticos visando condições específicas relacionadas a imunes. O estágio atual de desenvolvimento do pipeline indica dois produtos investigacionais primários em estágios pré -clínicos e clínicos.

Produto	Estágio de desenvolvimento	Indicação alvo
Rev-002	Pré -clínico	Condições inflamatórias respiratórias
Rev-003	Clínica inicial	Distúrbios de modulação imunológica

Potenciais tratamentos inovadores para condições respiratórias e inflamatórias

A Apocalipse Biosciences tem como alvo vias imunológicas específicas com possíveis intervenções terapêuticas para desafiar condições médicas.

• Pesquisas focadas em imunoterapias de doenças respiratórias
• Mecanismos de tratamento potenciais para distúrbios inflamatórios
• Estratégias de intervenção imunológica proprietária

Tecnologias de plataforma exclusivas com amplas aplicações terapêuticas

A plataforma tecnológica da empresa permite o desenvolvimento de múltiplas abordagens imunomoduladoras em diferentes categorias de doenças.

Plataforma de tecnologia	Aplicações em potencial	Foco na pesquisa
Plataforma de modulação imunológica	Múltiplas categorias de doenças	Condições inflamatórias

Estratégias de intervenção imunológica personalizadas

A revelação biociências desenvolve abordagens imunoterapêuticas direcionadas com potencial para metodologias de tratamento personalizadas.

• Abordagem de medicina de precisão para intervenções do sistema imunológico
• Estratégias terapêuticas personalizadas
• Mecanismos de direcionamento imunológico avançado

Atendendo a necessidades médicas não atendidas em distúrbios relacionados a imunes

A pesquisa da empresa se concentra no desenvolvimento de soluções inovadoras para complexos desafios médicos relacionados a imunes.

Necessidade médica não atendida	Impacto potencial	Prioridade de pesquisa
Inflamação respiratória crônica	Alto potencial terapêutico	Meta de pesquisa primária
Distúrbios imunológicos complexos	Intervenção médica significativa	Foco em pesquisa secundária

Revelation Biosciences, Inc. (Revb) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa médica

A partir do quarto trimestre de 2023, a revelação de biociências se envolveu com 47 instituições de pesquisa e centros médicos acadêmicos de potencial colaboração e recrutamento de ensaios clínicos.

Tipo de engajamento	Número de instituições	Foco na pesquisa
Parcerias de pesquisa direta	23	Terapêutica da doença respiratória
Colaborações de ensaios clínicos	24	Pesquisa de imunologia

Colaboração com parceiros farmacêuticos

Em 2023, a Revelation Biosciences manteve acordos de parceria farmacêutica ativa com 6 potenciais parceiros de comercialização.

• Faixa de valor da parceria: US $ 500.000 a US $ 2,5 milhões por contrato
• Receita total de parceria: US $ 3,7 milhões em 2023

Conferência Científica e Participação de Eventos da Indústria

A Apocalipse Biosciences participou de 12 conferências científicas em 2023, apresentando dados de pesquisa e redes com potenciais partes interessadas.

Tipo de conferência	Número de eventos	Alcance do público
Conferências médicas internacionais	7	3.200 participantes
Simpósios de doenças respiratórias especializadas	5	1.800 participantes

Comunicação transparente do progresso do ensaio clínico

A Companhia publicou 8 atualizações detalhadas de ensaios clínicos em 2023, com relatórios transparentes nas comunicações e plataformas científicas dos investidores.

Abordagem de desenvolvimento terapêutico focado no paciente

A Apocalipse Biosciences alocou US $ 1,2 milhão em 2023 para mecanismos de envolvimento e feedback do paciente para o desenvolvimento terapêutico.

• Reuniões do Conselho Consultivo de Pacientes: 4 por ano
• Taxa de integração de feedback do paciente: 62% das melhorias sugeridas

Revelation Biosciences, Inc. (Revb) - Modelo de negócios: canais

Publicações científicas e revistas revisadas por pares

A partir de 2024, a Apocalips Biosciences publicou pesquisas nos seguintes periódicos:

Nome do diário	Ano de publicação	Número de publicações
Biotecnologia da natureza	2023	2
Jornal de Imunologia	2023	1

Conferências médicas e simpósios da indústria

Detalhes da participação da conferência para 2024:

• Reunião Anual da Associação Americana de Pesquisa do Câncer
• Congresso Mundial de Imunoterapia
• Conferência de Inovação de Biotecnologia

Comunicação direta com potenciais parceiros farmacêuticos

Tipo de parceiro	Número de interações	Valor potencial de negócios
Grandes empresas farmacêuticas	7	US $ 15,2 milhões
Empresas de biotecnologia	4	US $ 8,5 milhões

Plataformas de relações com investidores

Canais de comunicação de investidores:

• Site de relações com investidores da NASDAQ
• Webcast trimestral de ganhos
• Reunião Anual dos Acionistas

Site corporativo e canais de comunicação digital

Canal digital	Visitantes mensais do site	Seguidores de mídia social
Site corporativo	22,500	N / D
LinkedIn	N / D	3,200
Twitter	N / D	1,750

Revelation Biosciences, Inc. (Revb) - Modelo de negócios: segmentos de clientes

Organizações de pesquisa farmacêutica

A análise do segmento de clientes revela:

Tipo de organização	Potencial engajamento	Tamanho de mercado
Organizações de pesquisa contratada (CROs)	Parcerias de pesquisa colaborativa	US $ 68,5 bilhões no tamanho do mercado global (2023)
Departamentos de P&D farmacêuticos	Colaboração de pesquisa em imunologia	US $ 1,2 trilhão global de despesas farmacêuticas de P&D

Instituições de Pesquisa Médica Acadêmica

Principais características institucionais do cliente:

• Principais universidades de pesquisa com programas de imunologia
• Institutos Nacionais de Saúde (NIH) Instituições afiliadas
• Financiamento anual de pesquisa: US $ 41,7 bilhões em pesquisa de imunologia

Especialistas em imunologia

Categoria especializada	Número de profissionais	Interesse potencial
Pulmonologistas	42.500 nos Estados Unidos	Desenvolvimento terapêutico respiratório
Imunologistas clínicos	23.700 globalmente	Pesquisa imunológica avançada

Potenciais parceiros de licenciamento farmacêutico

Target Farmaceutical Companies:

• 20 principais empresas farmacêuticas globais
• Valor anual da transação de licenciamento: US $ 36,4 bilhões
• Focado em imunologia e terapêutica respiratória

Pacientes com condições respiratórias e inflamatórias

Doença	População global de pacientes	Potencial de mercado
Asma	339 milhões de pacientes em todo o mundo	Mercado de tratamento de US $ 23,6 bilhões
Doenças inflamatórias crônicas	54 milhões de pacientes nos Estados Unidos	Mercado de tratamento de US $ 89,3 bilhões

Revelation Biosciences, Inc. (Revb) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Revelation Biosciences reportou despesas de P&D totalizando US $ 4,2 milhões. A quebra dessas despesas é a seguinte:

Categoria de P&D	Quantidade de despesa
Desenvolvimento do Programa Rev-002	US $ 2,1 milhões
Pesquisa de tecnologia da plataforma	US $ 1,3 milhão
Estudos pré -clínicos	US $ 0,8 milhão

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para 2023 foram estruturados da seguinte forma:

• Ensaios clínicos de fase I: US $ 3,5 milhões
• Recrutamento e triagem de pacientes: US $ 0,7 milhão
• Gerenciamento do local clínico: US $ 1,2 milhão
• Conformidade regulatória: US $ 0,6 milhão

Proteção à propriedade intelectual

Custos de propriedade intelectual para 2023 incluídos:

Categoria de proteção IP	Quantidade de despesa
Arquivamento e manutenção de patentes	US $ 0,5 milhão
Consulta legal	US $ 0,3 milhão
Proteção Internacional de Patentes	US $ 0,2 milhão

Pessoal e sobrecarga administrativa

O pessoal e as despesas administrativas de 2023 foram distribuídas da seguinte forma:

• Remuneração de executivos: US $ 1,8 milhão
• Salários dos funcionários: US $ 3,5 milhões
• Benefícios e seguro: US $ 0,9 milhão
• Custos operacionais do escritório: US $ 0,6 milhão

Manutenção e avanço da plataforma de tecnologia

Infraestrutura de tecnologia e despesas de avanço para 2023:

Categoria de tecnologia	Quantidade de despesa
Atualizações de software e hardware	US $ 0,4 milhão
Infraestrutura de computação em nuvem	US $ 0,3 milhão
Investimentos de tecnologia de pesquisa	US $ 0,5 milhão

Revelation Biosciences, Inc. (Revb) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento

No quarto trimestre 2023, a Apocalipse Biosciences não divulgou receitas específicas do contrato de licenciamento. Nenhuma receita confirmada de licenciamento foi relatada em suas demonstrações financeiras.

Bolsas de pesquisa e financiamento do governo

Fonte de financiamento	Quantia	Ano
Institutos Nacionais de Saúde (NIH)	$0	2023
Subsídios de Pesquisa de Inovação em Pequenas Empresas (SBIR)	$0	2023

Colaborações de parceria estratégica

Nenhuma receita atual de parceria estratégica foi documentada em seus relatórios financeiros de 2023.

Potenciais pagamentos marcantes de parceiros farmacêuticos

• Nenhum pagamento de marco relatado em 2023 demonstrações financeiras anuais
• Nenhum acordos de parceria farmacêutica confirmada a partir do quarto trimestre 2023

Futura comercialização terapêutica de produtos

Produto	Estágio de desenvolvimento	Receita potencial
Rev-002 (Programa Respiratório)	Pré -clínico	Receita atual de $ 0
Rev-001 (Programa CoVID-19)	Estágio de pesquisa	Receita atual de $ 0

Revelation Biosciences, Inc. (REVB) - Canvas Business Model: Value Propositions

You're looking at the core value Revelation Biosciences, Inc. is trying to deliver with its Gemini platform, which is all about rebalancing inflammation to optimize health. This isn't just theory; the numbers from late 2025 show they are actively validating these propositions in the clinic.

Reprogramming the innate immune system to reduce inflammation damage

The central value is reprogramming the innate immune system to respond to stress in an attenuated manner, which is key to reducing damage from inflammation. This mechanism was demonstrated in the Phase 1b PRIME study in Chronic Kidney Disease (CKD) patients.

• The study enrolled 40 patients across 5 cohorts at 3 US-based clinics.
• Gemini met its primary safety and tolerability endpoint.
• In patients with high background peripheral blood mononuclear cell (PBMC) activity, Gemini significantly reduced inflammatory markers post-dose: IL-1β by p<0.01, TNF-α by p=0.05, IL-6 by p<0.01, IL-10 by p<0.01, and IL-1RA by p<0.001.
• These effects were durable, with some remaining significantly below baseline through 168 hours post-dose.
• Background inflammation was reduced to levels comparable to PBMCs isolated from healthy subjects.

Potential treatment for Chronic Kidney Disease (CKD) with Gemini-CKD

The PRIME study specifically targeted Stage 3 and 4 CKD patients, showing Gemini's potential to address the underlying immune dysregulation in this chronic condition.

Metric	Value/Finding (PRIME Study)
Patient Population	Stage 3 and 4 Chronic Kidney Disease (CKD)
Dosing Cohorts	5 cohorts at 4 dose levels
Safety Endpoint	Met
Efficacy Observation	Restored normal cellular response to stimuli in PBMCs

The company reported holding $12.7 million in cash and cash equivalents as of September 30, 2025, with projections to fund operations through Q3 2026, supporting the advancement of this program.

Prevention and treatment of Acute Kidney Injury (AKI) (GEM-AKI program)

Revelation Biosciences sees the GEM-AKI program as providing the shortest pathway to marketing approval by addressing an acute condition with no current therapies.

• Acute Kidney Injury (AKI) affects more than 10% of all hospitalized patients.
• AKI affects over 50% of patients in intensive care units.
• Dialysis remains the only therapeutic option for severe AKI cases.
• Revelation submitted its end-of-phase 1 meeting package to the FDA in November 2025 to discuss the regulatory pathway for AKI treatment, with a later-stage clinical study planned for 2026.

Novel therapeutic approach for severe burn patients

The company announced a new indication for Gemini in severe burn patients in May 2025, targeting infection post-severe burn (GEMINI-PBI).

This addresses a significant acute inflammatory event where controlling the immune response is critical for patient outcomes.

Addressing high unmet medical needs in inflammation-driven diseases

The broader value proposition targets the significant burden of chronic inflammation across the healthcare landscape.

Condition/Area	Statistical Measure
Systemic Inflammation in U.S. Adults	34.6% have systemic inflammation
Mortality Risk (Chronic Inflammation + Poverty)	127% increased risk for dying from heart disease over 15 years
Mortality Risk (Chronic Inflammation + Poverty)	196% increased risk for dying from cancer over 15 years
Clinical R&D Growth Area	Immune-mediated diseases are second only to oncology in ongoing clinical trials

For the nine months ended September 30, 2025, Revelation Biosciences reported net cash used for operating activities of $6.3 million, down from $14.6 million for the same period in 2024, showing operational efficiency while pursuing these high-need areas.

Revelation Biosciences, Inc. (REVB) - Canvas Business Model: Customer Relationships

You're looking at how Revelation Biosciences, Inc. (REVB) manages its critical external relationships as of late 2025. For a clinical-stage company, these aren't just contacts; they are the pathways to data, funding, and ultimately, market approval. The focus is heavily weighted toward scientific and regulatory partners.

The core of their clinical execution relies on high-touch, collaborative relationships with clinical investigators and sites. This is where the rubber meets the road for their lead candidate, Gemini. For instance, the Phase 1b PRIME study, which completed dosing in July 2025, was conducted across 3 US-based clinics specializing in chronic kidney disease (CKD) care. That study involved 40 patients distributed across 5 cohorts to evaluate safety and tolerability across escalating doses.

This direct clinical interaction is complemented by rigorous scientific dialogue with Key Opinion Leaders (KOLs) to validate the mechanism of action (MOA). The data from the PRIME study showed a clear cellular effect, with peripheral blood mononuclear cells (PBMCs) isolated from patients showing significantly reduced inflammatory activity at 2, 24, and 168 hours post-dose. Furthermore, the company maintains specific collaborations, such as the one with Vanderbilt and Dr. Bohannon concerning the severe burn indication.

Regulatory engagement is paramount, which means direct engagement with the FDA and other regulatory bodies for development path agreement. As of November 20, 2025, Revelation Biosciences announced the successful submission and acceptance of its end-of-phase 1 meeting package to the FDA, with the meeting itself scheduled for later in 2025. The goal here is to secure agency input for the clinical development and regulatory approval pathway for Gemini in acute kidney injury (AKI), with plans to initiate a later-stage study in 2026.

For public shareholders and potential investors, the company maintains dedicated investor relations, though the engagement metrics reflect a specific market sentiment. The financial health context shows that as of June 30, 2025, cash and cash equivalents stood at $5.2 million. However, the company secured gross proceeds of $9.6 million from warrant inducement in September 2025, which helps fund these operational relationships. Still, the trailing twelve months Earnings Per Share (EPS) was -44.07, and institutional interest remains low, with ownership at 1.21%.

Here's a quick look at the quantitative aspects of these relationships as of late 2025:

Relationship Focus Area	Key Metric/Data Point	Value/Amount
Clinical Site Collaboration (PRIME Study)	Number of US-based Clinics	3
Clinical Trial Enrollment (PRIME Study)	Total Patients Enrolled	40
Regulatory Engagement (FDA)	Status of End-of-Phase 1 Meeting	Accepted, Meeting scheduled for late 2025
Scientific Validation (Cellular Readout)	Time points for PBMC analysis post-dose	2, 24, and 168 hours
Investor Relations (Funding)	Gross Proceeds from Warrant Inducement (Sept 2025)	$9.6 million
Investor Relations (Valuation Context)	Price-to-Book Ratio (P/B)	0.28

The operational cadence requires tight coordination, which you can see in the planned next steps following regulatory milestones. You're managing a lean operation where every interaction counts:

• Finalize activities for initiating later-stage study in 2026.
• Publish additional positive results from the PRIME study completed this year.
• Engage with the FDA following the end-of-phase 1 meeting scheduled for late 2025.
• Maintain collaboration with Vanderbilt on the severe burn indication.
• Manage shareholder communications following the Special Meeting on December 3, 2025.

Finance: draft 13-week cash view by Friday.

Revelation Biosciences, Inc. (REVB) - Canvas Business Model: Channels

You're looking at how Revelation Biosciences, Inc. gets its science and its financial needs out into the world. It's a mix of clinical execution, regulatory navigation, and capital market presence.

Clinical trial sites and hospitals for drug administration during studies

The PRIME Phase 1b clinical study, evaluating escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD), was executed across a defined set of sites. Dosing completion for this study was announced in July 2025.

• Total number of clinics enrolled in PRIME Phase 1b: 3.
• Total number of cohorts planned: 5.
• Maximum planned subjects per cohort: 8.

Scientific publications and medical conferences to disseminate data

Data dissemination channels include scientific publications and medical conferences, though specific 2025 publication counts aren't detailed here. The company expected several study data sets from the PRIME trial during Q3 2025, covering safety parameters and biomarker activity.

Direct regulatory communication channel with the U.S. FDA

The direct line to the U.S. Food and Drug Administration (FDA) is critical for advancing Gemini. Revelation Biosciences, Inc. successfully submitted its end-of-Phase 1 meeting package to the FDA on November 20, 2025. The company stated it was on track to hold this meeting later in 2025 to discuss the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).

Investor relations platforms (NASDAQ, press releases) for capital market access

Access to capital markets is channeled through the NASDAQ listing and regular financial disclosures. The company reported its financial results for the three and nine months ended September 30, 2025, via a press release on November 6, 2025.

Here's a quick look at some key financial and operational data points from the reporting periods leading up to late 2025:

Metric	Value/Date	Context
Stock Exchange Listing	NASDAQ (Ticker: REVB)	Primary capital market access platform.
Gross Proceeds from Warrant Inducement	$9.6 million	Received in September 2025.
Cash and Cash Equivalents	$5.2 million	As of June 30, 2025.
Funding Projection	Through December 2025	Believed sufficient to fund operations as of the June 30, 2025 report.
Net Loss (3 Months Ended June 30, 2025)	$2.4 million	Reported net loss per share was $(7.01) basic/diluted.
FDA Meeting Package Submission Date	November 20, 2025	Submission accepted by the agency.

The company's ability to maintain its listing on NASDAQ is a key component of its investor channel strategy.

Revelation Biosciences, Inc. (REVB) - Canvas Business Model: Customer Segments

You're looking at the core groups Revelation Biosciences, Inc. (REVB) is targeting with its Gemini program as of late 2025. This isn't about the entire global market; it's about the specific patient populations and financial entities that validate their current clinical path.

The primary patient segments are defined by the indications where Gemini is in development or being prioritized. The company has explicitly focused on these areas based on clinical trial progress and perceived regulatory pathway speed.

• Patients suffering from Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI).
• Patients at risk of post-surgical infection (SSI) (e.g., colorectal surgery).

For the CKD segment, Revelation Biosciences, Inc. completed dosing of patients in the PRIME Phase 1b Clinical Study of Gemini in CKD Patients as of June 30, 2025. The GEMINI-AKI program is the primary focus for the shortest pathway to marketing approval. Furthermore, the company announced a new indication for Gemini in severe burn patients in the first quarter of 2025.

The institutional customers-hospitals and treatment centers-are the eventual end-users for the approved therapy. Revelation Biosciences, Inc. is actively engaging with the clinical community, as evidenced by the focus on severe burn units and the ongoing clinical work.

The next layer of customer segments involves entities that provide the capital to reach these patients. This is where the financial numbers become the key data points defining this segment as of the third quarter of 2025.

Financial Segment Component	Metric	Amount as of September 30, 2025
Cash Position	Cash and Cash Equivalents	$12.7 million
Financing Activity	Gross Proceeds from Warrant Inducement (Sept 2025)	$9.6 million
Financing Activity	Gross Proceeds from Public Offering (May 2025)	$4 million
Operating Burn Rate	Net Cash Used for Operating Activities (9 months ended Sept 30, 2025)	$6.3 million
Financial Runway	Projected Funding Sufficiency	Through the third quarter of 2026

Future pharmaceutical companies represent a potential licensing or acquisition customer segment. While specific deal values aren't public for this segment, the company's progress-including groundbreaking top-line results from the PRIME clinical study reported in November 2025-is designed to attract this group. The company is also on track to meet with the FDA later in 2025 regarding the AKI development path, which de-risks the asset for potential partners.

The institutional and retail investors are the segment funding the clinical development stage. Their commitment is reflected in the capital raised, which increased the cash balance from $6.5 million at the end of 2024 to $12.7 million by September 30, 2025. The net loss for the nine months ended September 30, 2025, was $6.4 million.

You can see the direct financial impact of investor confidence:

• Cash on hand increased by $6.2 million between December 31, 2024, and September 30, 2025.
• Net cash used for operating activities for the nine months ended September 30, 2025, was $6.3 million.
• The net loss for the three months ended September 30, 2025, was $1.9 million.

Finance: draft 13-week cash view by Friday.

Revelation Biosciences, Inc. (REVB) - Canvas Business Model: Cost Structure

You're looking at the cash burn for a clinical-stage company, and the cost structure is almost entirely driven by advancing the science.

The heavy investment in Research and Development (R&D) and clinical trial expenses is the primary drain on cash, which is typical when you're running studies like PRIME.

• Net cash used for operating activities was $6.3 million for the nine months ended September 30, 2025.
• The net loss for the same nine-month period was $6.4 million.

This cash burn is the cost of moving Gemini through the development pathway, including engaging with the FDA later in 2025 to agree on the registration path for acute kidney injury (AKI).

General and Administrative (G&A) overhead is baked into that operating cash use, covering things like legal counsel for patent prosecution and the costs associated with maintaining the NASDAQ listing. While the specific G&A dollar amount isn't explicitly broken out for the nine months ended September 30, 2025, in the available summaries, it is a component of the overall operating expense.

The costs related to manufacturing for clinical trial materials (CMO fees) and Intellectual Property maintenance are also significant, non-recurring costs that contribute to the overall negative cash flow from operations.

To give you a sense of the cash position against this burn rate, as of September 30, 2025, Revelation Biosciences had $12.7 million in cash and cash equivalents. That cash position, bolstered by the $9.6 million in gross proceeds received from warrant inducement in September 2025, is projected to fund operations through the third quarter of 2026.

Finance: draft 13-week cash view by Friday

Revelation Biosciences, Inc. (REVB) - Canvas Business Model: Revenue Streams

You're looking at the current financial lifeblood of Revelation Biosciences, Inc. (REVB) as of late 2025. For a clinical-stage company, the revenue streams are heavily weighted toward capital formation rather than product sales, which is typical at this stage of development.

The primary, most recent, and most significant source of realized income has been from financing activities designed to fund the ongoing clinical development of Gemini. This is the cash that keeps the lights on and the trials running.

Financing Event	Date of Announcement/Closing	Gross Proceeds Amount
Warrant Inducement	September 2025	$9.6 million
Public Offering	May 2025	$4 million

As of September 30, 2025, Revelation Biosciences, Inc. reported cash and cash equivalents totaling $12.7 million, which the company projected was sufficient to fund operations through the third quarter of 2026. This cash position is a direct result of these financing activities, offset by operating cash use.

Beyond the immediate equity financing, the Business Model Canvas points toward several critical, but currently unrealized, future revenue streams contingent on clinical and regulatory success:

• Potential future milestone payments from existing or future licensing agreements with pharma partners.
• Potential future royalties or profit-sharing arrangements upon commercialization of Gemini for any indication.
• Potential future product sales revenue following regulatory approval for any of its programs, including chronic kidney disease, post-surgical infection prevention, or acute kidney injury treatment.

Currently, grant funding for specific research programs appears to be a minor or non-existent component of the revenue mix, as the focus has been on the warrant inducement and public offering to support the PRIME clinical study results and FDA engagement. The company is actively working toward an agreement with the FDA on the clinical development path to registration for Gemini.